Compare AbCellera Biologics Inc (ABCL) vs Mongodb Inc (MDB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Mongodb Inc — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Mongodb Inc trades at $356.8 (market cap $29.06B). The key difference: Mongodb Inc is far larger — about 12.4× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | MDB | |
|---|---|---|
Market Cap | $2.35B | $29.06B |
Sector | Health | Technology |
52-Week High | $8.12 | $440.25 |
52-Week Low | $2.78 | $201.08 |
Enterprise Value | $1.99B | $26.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MongoDB (MDB) trades at $361.32, up 1.81% with a bullish technical trend and strong analyst support. Recent earnings beats and revenue growth to $2.01B in 2025 highlight operational momentum, though profitability remains negative. The stock faces overbought signals near-term but benefits from AI-driven demand and raised 2026 guidance.
Outlook is positive with a $399.05 consensus price target, but risks include high valuation multiples, ongoing losses, and legal scrutiny. Investors should weigh robust growth against profitability challenges and market volatility for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
